Skip to main content
. 2024 May 14;26(1):20. doi: 10.1007/s12017-024-08781-6

Fig. 2.

Fig. 2

Role of Endocannabinoid System in Pathophysiology of ASD. CB1 and CB2 receptors can work as a potential therapeutic target of ASD. Rimonabant & NESS0327 targets CB1; whereas AM630 targets CB2